Αρχική World News First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in... World News First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma Από Ogkologos - 24 Μαρτίου, 2026 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Self Destruction 8 Σεπτεμβρίου, 2022 Reflecting on COVID-19 and the Importance of Providing Information to People... 21 Ιουλίου, 2022 Wales: 4 in 10 with possible cancer symptoms didn’t contact GP 17 Ιουνίου, 2021 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... 27 Αυγούστου, 2025 Φόρτωση περισσοτέρων HOT NEWS ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health Change Your Thoughts, Change Your World